FDA Rejects Xarelto Bleeding Antidote

xarelto antidote graphicPortola Pharmaceuticals was dealt a blow when its breakthrough drug AndexXa was turned down by health regulators earlier this month. The U.S. Food and Drug Administration (FDA) says it needs more information  before approving a new antidote for life-threatening bleeding linked to blood thinners like Xarelto and Eliquis.

AndexXa (andexanet alfa) was a first-in-class medication designed to reverse uncontrollable bleeds in patients taking direct or indirect Factor Xa inhibitors, including: apixaban, rivaroxaban, edoxaban and enoxaparin. AndexXa, an FDA-labeled Breakthrough Therapy, was fast-tracked for review and approval to address a mounting number of life-threatening bleeding events associated with blood thinners.

Despite promising results in early AndexXa trials, the FDA rejected the drug, and sent Portola a “Complete Response Letter.” The letter, sent on August 16, asks for additional data on manufacturing processes that may help facilitate inclusion of enoxaparin and edoxaban on AndexXa drug labels. The agency also needs more time to further evaluate the drug manufacturer’s post-marketing strategies.

Possible Xarelto antidote rejected by FDA

Portola’s pre-market studies included the ANNEXA-A trial, which demonstrated the superior anticoagulant effects of AndexXa in patients taking Eliquis. According to the results, the drug rapidly reversed uncontrolled bleeds by 93.5 percent within a span of two hours.

After AndexXa’s drug application was turned down, Bill Lis, CEO of Portola, expressed the firm’s intentions in the following statement: “Because AndexXa addresses an urgent unmet medical need, we and the FDA are committed to resolving the outstanding questions and determining appropriate next steps. Portola’s goal is to define the most expedient path to approval so we can meet the needs of these patients who have no alternative… We plan to meet with the FDA as soon as possible.”

Xarelto bleeding injuries and deaths

Since hitting the shelves in 2011, Xarelto has been associated with a large number (more than 2,000) of adverse events related to internal bleeding.  In addition, dozens of Xarelto patients have died from uncontrolled hemorrhaging. With no effective bleeding antidote at their disposal, Xarelto patients are at risk for life-threatening injury. It is argued that Johnson & Johnson/Bayer manufactured and marketed Xarelto without sufficient warnings, and even promoted the drug as a safer alternative to Coumadin (warfarin).

Thousands of patients have pursued Xarelto litigation after suffering serious harm or the loss of a loved one. According to Xarelto lawsuits and adverse event reports submitted to the FDA, the blood thinner is associated with a high risk of:

  • Gastrointestinal bleeding
  • Cerebral hemorrhage and vascular accidents
  • Hemorrhagic stroke
  • Peripheral edema
  • Hematoma
  • Uncontrolled bleeds requiring hospitalization and transfusion
  • Death

The law firm of Nadrich & Cohen, LLP believes that Big Pharma owes a duty to label their products correctly and inform consumers about known health risks. When this obligation is breached, victims have the right to pursue a product liability claim, or in some cases, a wrongful death lawsuit.

To learn more about filing a Xarelto bleeding claim, we invite you to schedule a free consultation. Call 1-800-718-4658 to speak with a skilled California personal injury lawyer today.

Additional Xarelto Resources:

  1. PharmaTimes, Portola’s blood thinner antidote turned away by FDA
  2., FDA rejects Portola’s anticoagulant antidote AndexXa

Do I Have A Case?

We offer free consultation. No office visit required, we will get back to you within 24 hours.

  • This field is for validation purposes and should be left unchanged.


What can we do for you?

  • Answer your legal question.
  • Provide a Free Case Evaluation.
  • Schedule an appointment.


Choose Us?

  • Available 24/7
  • Trusted Since 1990
  • Local to You
  • Recovered $350,000,000
  • 5 Star Reviews
  • Free Case Evaluation
  • VIP Service
  • No Win, No Fee

Latest Law Post

March 15, 2019

Expert Testifies Before House Subcommittee Regarding Talc Use And Ovarian Cancer Link

A United States House of Representatives subcommittee, on March 12th, 2019, looked into whether they should give the Food and Drug Administration (FDA) the power to more strictly regulate cosmetics, including talcum powder and products containing talc.

March 13, 2019

IVC Filters Used for Blood Clots Come With Risks, Complications


We are Personal Injury Lawyers representing accident victims throughout California.
For 30 years, the law firm of Nadrich & Cohen, LLP has helped injury victims
obtain the compensation they deserve.